A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Nivolumab (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2019 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.
- 26 Jul 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.
- 26 Jul 2019 Status changed from not yet recruiting to recruiting.